StockNews.com Begins Coverage on Cytosorbents (NASDAQ:CTSO)

Equities researchers at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO - Get Free Report) in a research note issued on Tuesday. The firm set a "hold" rating on the medical research company's stock.

Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Cytosorbents in a research note on Tuesday, February 25th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Cytosorbents currently has an average rating of "Moderate Buy" and an average target price of $4.67.

Cytosorbents Price Performance

Cytosorbents stock traded down $0.03 during midday trading on Tuesday, reaching $1.10. 37,298 shares of the stock traded hands, compared to its average volume of 145,600. The stock's fifty day moving average is $1.06 and its 200-day moving average is $1.05. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.61. The stock has a market cap of $60.15 million, a P/E ratio of -3.06 and a beta of 0.78. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Remove Ads

Institutional Investors Weigh In On Cytosorbents

Several hedge funds and other institutional investors have recently modified their holdings of CTSO. Millennium Management LLC purchased a new stake in shares of Cytosorbents in the fourth quarter worth approximately $30,000. Renaissance Technologies LLC raised its holdings in shares of Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company's stock worth $80,000 after buying an additional 8,400 shares during the period. Northern Trust Corp raised its holdings in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Cytosorbents in the fourth quarter worth approximately $99,000. Finally, Geode Capital Management LLC raised its holdings in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after buying an additional 32,415 shares during the period. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.